NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
NeuroPace, Inc. (NPCE) files its annual report describing a focused neuromodulation business built around the RNS System, a brain-responsive implant that monitors electrical activity and delivers targeted stimulation to prevent seizures in adults with drug‑resistant focal epilepsy.
The company highlights extensive clinical data showing long‑term seizure reduction, quality‑of‑life gains and a favorable safety profile versus resective surgery and other neuromodulation devices. As of December 31, 2025, over 8,000 patients had received the RNS System, supporting a U.S. target market of about 575,000 adults with drug‑resistant focal epilepsy and a broader 1.2 million drug‑resistant epilepsy population.
NeuroPace is pursuing growth by deepening penetration in Level 4 epilepsy centers, expanding into community practices, seeking FDA label expansions into idiopathic generalized epilepsy and pediatric patients, and selectively entering international markets. In February 2025 it raised approximately $69.7 million in net equity proceeds, using $49.5 million to repurchase shares from major stockholder KCK Ltd. and reserving the balance for general corporate purposes.
NeuroPace, Inc. reported strong growth for Q4 and full year 2025 while narrowing losses and laying out 2026 guidance. Q4 2025 revenue rose 24% to $26.6 million, driven mainly by RNS System sales of $22.4 million (up 26% year over year). Total gross margin improved to 77.4%, and RNS gross margin reached 80.5%, helping cut Q4 net loss to $2.7 million from $5.3 million a year earlier.
For 2025, revenue increased 25% to $100.0 million, with RNS System revenue of $81.7 million also up 25%. Full‑year gross margin expanded to 77.2%, and Adjusted EBITDA improved to a loss of $5.0 million. Cash, cash equivalents and short‑term investments were $61.1 million at December 31, 2025, with long‑term debt of $58.9 million.
The company plans to report DIXI Medical as discontinued operations starting in Q1 2026 and issued 2026 guidance on a continuing‑operations basis. It targets $98–$100 million in 2026 revenue, reflecting 20–22% RNS growth, non‑GAAP gross margin of 81.5–82.5%, non‑GAAP operating expenses of $90–$92 million, and Adjusted EBITDA between ($9.0) and ($10.0) million.
NeuroPace CEO Joel Becker reported a tax-related share withholding tied to a restricted stock unit vesting. On February 27, 2026, 1,126 shares of common stock were withheld by the company at $14.58 per share to cover tax obligations. After this tax-withholding disposition, Becker directly owned 101,960 shares.
NeuroPace Inc's chief medical officer reports a small share disposition tied to tax withholding. On February 27, 2026, 358 shares of common stock were withheld at $14.58 per share to satisfy tax obligations from a restricted stock unit vesting, rather than an open-market sale. Following this tax-withholding disposition, Martha Morrell directly held 74,964 shares of NeuroPace common stock.
NeuroPace Inc's Chief Medical Officer, Martha Morrell, reported a tax-related share disposition. On February 20, 2026, 3,412 shares of common stock were withheld by the company at $14.34 per share to cover tax obligations from a restricted stock unit vesting. After this withholding, she directly owned 75,322 shares of NeuroPace common stock.
NeuroPace, Inc. (NPCE) chief medical officer Form 4 filing reports an automatic share withholding related to equity compensation. On 11/20/2025, 3,051 shares of common stock were withheld by the company at a price of $13.50 per share to cover tax obligations tied to the vesting of a restricted stock unit award. After this tax withholding event, the reporting officer beneficially owned 80,429 shares of NeuroPace common stock directly.
NeuroPace, Inc. (NPCE) reported Q3 2025 results with revenue of $27,354,000 versus $21,060,000 a year ago, reflecting strong year-over-year growth. Gross profit was $21,168,000, and the company recorded a net loss of $3,496,000 compared to a $5,452,000 loss in Q3 2024. Year-to-date, revenue reached $73,398,000 with a net loss of $18,736,000.
As of September 30, 2025, cash, cash equivalents and short-term investments totaled $60,000,000. Long-term debt was $58,748,000 after the June refinancing that repaid the CRG term loan and established a new MidCap term loan maturing in 2030. The company completed a February follow-on offering of 7,475,000 shares at $10.00 per share for net proceeds of $69,700,000 and used $49,500,000 to repurchase 5,270,845 shares from a significant stockholder at $9.40 per share.
Management states compliance with MidCap liquidity and revenue covenants, with trailing 12‑month RNS System net revenue of $77,000,000 as of September 30, 2025. The DIXI Medical U.S. distribution agreement expired on September 30, 2025 and is in a six‑month wind‑down period.
NeuroPace, Inc. (NPCE) reported it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release, dated November 4, 2025, is furnished as Exhibit 99.1.
The company clarified the information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings unless specifically referenced.
NeuroPace insider shares issued to director as compensation. Director Uri Geiger was issued 1,194 shares of NeuroPace common stock on 09/19/2025 at a reported per-share value of $9.94 under the company's non-employee director compensation policy in lieu of a quarterly cash retainer. After the issuance, Mr. Geiger directly beneficially owns 13,230 shares. He also reports indirect beneficial ownership of 4,432,948 shares held by Accelmed Partners II LP, for which he states sole voting and dispositive power via his role as managing partner of the general partner entities.
NeuroPace Inc. (NPCE) Form 4: Director Joseph Lacob was issued 1,131 shares of NeuroPace common stock on 09/19/2025 at a price of $9.94 per share under the company's non-employee director compensation policy in lieu of quarterly retainer fees. After the issuance, Mr. Lacob directly beneficially owns 13,211 shares and holds additional indirect holdings of 128,174 shares through Lacob Ventures LLC and 223,554 shares through LCT18 Investments, as disclosed on the Form 4. The filing was signed by an attorney-in-fact on 09/22/2025.